Nafarelin
Also known as: Synarel, nafarelin acetate, RS-94991, GnRH agonist (intranasal), nafarelin acetate nasal solution
GnRH receptor agonist — synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH); administered intranasally
What it is
Nafarelin (Synarel) is a hormone-suppressing nasal spray used to treat endometriosis pain and central precocious puberty in children. By temporarily switching off the body's sex hormone production, it shrinks endometrial tissue and halts early puberty progression. It is FDA-approved and delivered as a twice-daily nasal spray.
The scientific side
nafarelin is a synthetic agonist of gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LH-RH). It is structurally derived from native GnRH but carries amino acid substitutions that confer greater receptor binding affinity, slower enzymatic degradation, and a longer plasma half-life compared to the endogenous decapeptide. When administered intranasally, nafarelin is absorbed through the nasal mucosa and achieves therapeutic plasma concentrations within approximately 10–20 minutes, with systemic bioavailability averaging about 2.8% after a 400 mcg intranasal dose — sufficient to achieve the desired hormonal suppression given the compound's high intrinsic potency at GnRH receptors. The initial administration of nafarelin mimics the action of endogenous GnRH by stimulating pituitary gonadotroph cells, briefly increasing LH and FSH secretion. However, with continued twice-daily dosing, the pituitary GnRH receptors become progressively desensitized and downregulated, a process sometimes called receptor occupancy-induced uncoupling. This paradoxical desensitization leads to markedly reduced secretion of both LH and FSH within one to three weeks of treatment initiation. The sustained fall in circulating LH and FSH eliminates the gonadotropin drive to the ovaries, so estradiol production drops to concentrations similar to those seen in postmenopausal women. This hypoestrogenic state causes regression of estrogen-dependent endometrial implants and ameliorates the pain and dysmenorrhea associated with endometriosis. In children with central precocious puberty, the same mechanism halts the premature activation of the hypothalamic-pituitary-gonadal axis, suppressing sex steroid production and slowing the advance of secondary sexual characteristics and bone age. A mathematical pharmacokinetic/pharmacodynamic model of the human menstrual cycle has validated nafarelin's ability to suppress the hormonal cycle in a dose- and timing-dependent manner, correctly predicting LH, FSH, estradiol, and progesterone changes following both single and multiple nafarelin doses. The selectivity of nafarelin is notable: unlike danazol, nafarelin interacts only with the pituitary GnRH receptor and does not bind androgenic, glucocorticoid, or other steroid receptors, which explains its more favorable androgenic side-effect profile relative to danazol. Following cessation, gonadotropin secretion and ovarian function recover, with most women resuming menses within 4–8 weeks.
Class: GnRH receptor agonist — synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH); administered intranasally
Legal & regulatory status
FDA-approved (NDA 019886) as Synarel (nafarelin acetate) nasal solution 2 mg/mL. Approved for two indications: (1) endometriosis — management of pelvic pain and reduction of endometriotic lesions in women; treatment…
Nafarelin and all GnRH agonists are prohibited under the WADA Prohibited List. As a peptide hormone modulator capable of suppressing endogenous sex hormone production, nafarelin falls under Section S2 (Peptide Hormones,…
Nafarelin acetate (Synarel) is approved in Canada for the treatment of endometriosis and central precocious puberty, consistent with its FDA-approved indications. Listed as a Schedule F prescription drug under the Food…
What it's studied for
- Endometriosis — reduction of pelvic pain, dysmenorrhea, and endometrial implants Phase III RCT
- Endometriosis — quality of life and comparative safety versus danazol Human RCT
- Central precocious puberty (CPP) in children Human observational
- Assisted reproductive technology (IVF) — controlled ovarian hyperstimulation protocols Human RCT
- Uterine leiomyomas (fibroids) — preoperative size reduction and symptom control Human observational
- Bone metabolism and calcium regulation during GnRH agonist-induced ovarian suppression Human observational
- Acute porphyria (hereditary coproporphyria) — suppression of hormone-triggered attacks in women Mechanistic only
Safety signals
- Hot flashes and vasomotor symptoms due to hypoestrogenemia
- Bone mineral density (BMD) loss — reversible trabecular bone resorption
- Vaginal dryness, decreased libido, and sexual dysfunction
- Depressive mood symptoms and emotional lability
- Nasal irritation and local tolerability issues related to intranasal route
- Initial hormonal flare — transient LH/FSH surge at treatment initiation
- Headaches as a commonly reported adverse effect
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Unspecified | 200 mcg per nostril (one spray each nostril) twice daily = 400 mcg/day total | — | Adult women — endometriosis (FDA-approved indication) | Research |
| Unspecified | 800 mcg/day initially (two sprays in alternating nostrils, morning and evening); may increase to 1600 mcg/day if suppression is inadequate | — | Children — central precocious puberty (FDA-approved indication) | Research |
| Unspecified | 400 mcg twice daily (nafarelin 400 mcg bid intranasally) | — | Adult women — IVF ovarian stimulation pretreatment (off-label/investigational) | Research |
| Unspecified | 50–400 mcg twice daily intranasally | — | Adult women — uterine leiomyomas (off-label) | Research |
| intranasal spray — one spray (200 mcg) into each nostril | 200 mcg per nostril twice daily (total 400 mcg/day) | twice daily, approximately 12 hours apart | adult women with endometriosis-related pelvic pain, dysmenorrhea, or dyspareunia |